A detailed history of Group One Trading, L.P. transactions in Compass Pathways PLC stock. As of the latest transaction made, Group One Trading, L.P. holds 239,882 shares of CMPS stock, worth $2.05 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
239,882
Previous 45,616 425.87%
Holding current value
$2.05 Million
Previous $389,000 426.48%
% of portfolio
0.09%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
N/A
194,266 Added 425.87%
239,882 $2.05 Million
Q2 2024

Aug 14, 2024

BUY
N/A
31,213 Added 216.71%
45,616 $389,000
Q1 2024

May 10, 2024

SELL
N/A
-15,585 Reduced 51.97%
14,403 $123,000
Q4 2023

Feb 14, 2024

BUY
N/A
29,988 New
29,988 $256,000
Q2 2023

Aug 09, 2023

SELL
$7.79 - $10.69 $832,330 - $1.14 Million
-106,846 Reduced 81.5%
24,250 $207,000
Q1 2023

May 12, 2023

BUY
$7.32 - $10.85 $564,716 - $837,044
77,147 Added 143.0%
131,096 $1.3 Million
Q4 2022

Feb 09, 2023

BUY
$7.84 - $11.68 $53,641 - $79,914
6,842 Added 14.52%
53,949 $433,000
Q3 2022

Nov 09, 2022

SELL
$10.73 - $20.07 $32,039 - $59,929
-2,986 Reduced 5.96%
47,107 $505,000
Q2 2022

Aug 11, 2022

SELL
$6.76 - $14.18 $797,923 - $1.67 Million
-118,036 Reduced 70.21%
50,093 $542,000
Q1 2022

May 12, 2022

BUY
$11.13 - $23.04 $671,205 - $1.39 Million
60,306 Added 55.93%
168,129 $2.17 Million
Q4 2021

Feb 11, 2022

BUY
$21.81 - $48.96 $1.95 Million - $4.38 Million
89,421 Added 485.93%
107,823 $2.38 Million
Q3 2021

Nov 12, 2021

BUY
$29.03 - $38.62 $534,210 - $710,685
18,402 New
18,402 $550,000
Q1 2021

May 12, 2021

SELL
$34.75 - $57.5 $119,991 - $198,547
-3,453 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$32.0 - $59.2 $110,496 - $204,417
3,453 New
3,453 $165,000

Others Institutions Holding CMPS

About COMPASS Pathways plc


  • Ticker CMPS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 42,522,400
  • Market Cap $363M
  • Description
  • COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...
More about CMPS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.